Photodynamic therapy with porphyrin and phthalocyanine sensitisation: quantitative studies in normal rat liver.

Selective sensitisation of malignant tumours to monochromatic light (photodynamic therapy, PDT) is a promising approach to cancer treatment, but current sensitisers are unsatisfactory and the parameters controlling effects produced in normal and neoplastic tissue are poorly understood. To quantify the effects in a relatively homogeneous organ, we carried out experiments in the livers of normal rats following systemic sensitisation with haematoporphyrin derivative (HpD) and a new sensitiser, a sulphonated aluminium phthalocyanine (AlSPc) using light from an Argon pumped tunable dye laser. Damage from PDT (dominant at 100 mW laser power) could be distinguished from that due to local hyperthermia (dominant at 400 mW). For both sensitisers, the extent of PDT necrosis increased with the applied light energy and was abolished by occluding the hepatic blood flow during therapy. With HpD, the extent of PDT necrosis was maximum with only a few hours between sensitisation and therapy, and was not detectable when this interval was increased to a week. With AlSPc, the extent of necrosis in liver changed little with sensitisation times from 1 h to 1000 h (6 weeks), and declined slowly thereafter, matching the amount of AlSPc measurable by alkali extraction, although prolonged photosensitisation was not seen with AlSPc in muscle. Less cutaneous photosensitivity was seen with AlSPc than with HpD. AlSPc is easier to produce and handle than HpD, has a more appropriate strong absorption peak (at 675 nm) and from these results, warrants further study as a photosensitiser for PDT.

[1]  T J Dougherty,et al.  Photoradiation therapy. II. Cure of animal tumors with hematoporphyrin and light. , 1975, Journal of the National Cancer Institute.

[2]  D. Brault,et al.  The purification of haematoporphyrin IX and its acetylated derivatives , 1984 .

[3]  M C Berenbaum,et al.  In vivo biological activity of the components of haematoporphyrin derivative. , 1982, British Journal of Cancer.

[4]  T J Dougherty,et al.  The structure of the active component of hematoporphyrin derivative. , 1984, Progress in clinical and biological research.

[5]  T J Dougherty,et al.  Identification of singlet oxygen as the cytotoxic agent in photoinactivation of a murine tumor. , 1976, Cancer research.

[6]  J. Moan,et al.  Photodynamic effects of haematoporphyrin derivative on synchronized and asynchronous cells of different origin. , 1981, British Journal of Cancer.

[7]  J. Moan,et al.  Tissue distribution of 3H-hematoporphyrin derivative and its main components, 67Ga and 131I-albumin in mice bearing Lewis lung carcinoma. , 1984, Progress in clinical and biological research.

[8]  J. Moore Porphyrin Localisation and Treatment of Tumors , 1985 .

[9]  T. Mang,et al.  Tumor destruction and kinetics of tumor cell death in two experimental mouse tumors following photodynamic therapy. , 1985, Cancer research.

[10]  E. Ben-hur,et al.  The phthalocyanines: a new class of mammalian cells photosensitizers with a potential for cancer phototherapy. , 1985, International journal of radiation biology and related studies in physics, chemistry, and medicine.

[11]  N. R. Pimstone,et al.  Hematoporphyrin-Augmented Phototherapy: Dosimetric Studies In Experimental Liver Cancer In The Rat , 1982, Optics & Photonics.